Biomerieux
bioMérieux, a global leader in in vitro diagnostics, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1963, the company has consistently innovated in the fields of microbiology and molecular biology, achieving significant milestones such as the development of the first automated microbiology system. Specialising in diagnostic solutions for infectious diseases, bioMérieux offers a range of unique products, including rapid tests and automated systems that enhance laboratory efficiency and accuracy. Their commitment to quality and innovation has solidified their position as a trusted partner in healthcare, with notable achievements in improving patient outcomes through timely diagnostics. With a strong focus on research and development, bioMérieux continues to lead the way in advancing diagnostic technologies worldwide.
DitchCarbon Score
How does Biomerieux's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biomerieux's score of 64 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biomerieux's reported carbon emissions
In 2023, bioMérieux reported total greenhouse gas emissions of approximately 1,124,000,000 kg CO2e, with emissions distributed across various scopes: 23,000,000 kg CO2e (Scope 1), 39,000,000 kg CO2e (Scope 2), and 1,124,000,000 kg CO2e (Scope 3). The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030 compared to 2019 levels. Furthermore, bioMérieux aims for a more significant reduction of 63% in absolute Scope 1 and 2 emissions by 2034, also from a 2019 baseline. In addition to its direct emissions reduction goals, bioMérieux is focused on its supply chain, with a commitment that 67% of its suppliers will have science-based targets by 2026. This comprehensive approach reflects the company's dedication to addressing climate change and reducing its overall carbon footprint in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 26,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 39,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 891,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biomerieux is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
